Pfizer Inc. and BioNTech SE announced Wednesday that the final efficacy analysis of their vaccine candidate, BNT162b2, undergoing the phase 3 trial met all of the study’s primary efficacy endpoints. Biotech companies said the study indicated a 95 percent vaccine efficacy rate, close to the efficacy rate found in early …
Read More »Covid-19 Vaccine: 5 Things You Should Know About Pfizer’s Encouraging Trial Results
